Reported topline healthy volunteer
results for
next-generation STAT3 inhibitor TTI-109, confirming the prodrug design, improved tolerability and
reductions in
disease-relevant immune cell populations
Announced ulcerative colitis (UC) as the initial disease indication for TTI-109 and will host a
KOL webinar
on the clinical potential of TTI-109 in UC on August 19, 2026, at 11:00 a.m. ET
HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) — Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today reported its financial and operating results for the second quarter ended June 30, 2026, and provided a business update.
Recent Developments
- Reported topline results from the healthy volunteer study of its next-generation STAT3 inhibitor, TTI-109, confirming prodrug design, improved tolerability and pharmacodynamic evidence of STAT3 target engagement.
- TTI-109 delivered TTI-101-equivalent exposure with improved tolerability and, across the active dose range, reductions in cellular and humoral immune populations known to correlate with UC disease severity.
- Selected UC as the initial disease indication for TTI-109, based on its ability to modulate multiple pathogenic pathways downstream of STAT3 simultaneously.
- In UC, STAT3 acts as a single convergent node downstream of multiple signaling pathways implicated in disease progression, integrating immune dysregulation, inflammation and tissue remodeling.
- These findings are further supported by published clinical studies linking reductions in activated STAT3 with higher rates of clinical remission across multiple UC therapeutic classes.
- UC represents a large, underserved market, with more than 1.25 million patients diagnosed in the U.S. and an addressable market of approximately $3 billion in the U.S. and $9 billion globally.
- Announced that the Company will host a KOL webinar on the clinical potential of TTI-109 in UC featuring Randy Longman, MD, PhD (Weill Cornell Medicine) on August 19, 2026, at 11:00 a.m. ET.
Imran Alibhai, Ph.D., Chief Executive Officer of Tvardi, stated, “Since our last quarterly report, we have made significant progress in the clinical development of our STAT3 inhibitors. Regarding our next-generation STAT3 inhibitor, TTI-109, we were enthusiastic to see modulation of disease-relevant immune cell population even in healthy volunteers. We believe this bodes well for the development of TTI-109 in inflammatory and proliferative diseases, like UC.”
Key Upcoming Milestones
- August 19, 2026: KOL webinar with Randy Longman, M.D., Ph.D., on the UC treatment landscape and TTI-109. To register, please click here
- 4Q 2026: TTI-101 Phase 1b/2 HCC topline data
- 2027: Initiation of clinical trial of TTI-109 in UC, subject to clearance of Investigational New Drug (IND) application and additional funding
Second Quarter 2026 Financial Results
Research and development expenses for the three months ended June 30, 2026, were $4.0 million as compared to $5.8 million for the comparable period in 2025. The decrease was primarily driven by lower clinical costs associated with TTI-101, partially offset by higher development costs associated with TTI-109.
General and administrative expenses were $2.6 million for the three months ended June 30, 2026, as compared to $3.1 million for the three months ended June 30, 2025. The decrease was primarily driven by lower professional fees, reflecting higher accounting and consulting costs in the comparable 2025 period associated with the Company’s April 2025 merger, partially offset by higher legal and investor relations costs associated with operating as a public company.
Net loss for the three months ended June 30, 2026, was $6.5 million, compared to net income of $4.2 million for the three months ended June 30, 2025. Net income in the prior-year period reflected a $12.7 million non-cash gain from the change in fair value of the Company’s convertible notes, which converted into common stock in connection with the Company’s merger with Cara Therapeutics in April 2025.
Basic and diluted net loss per share attributable to common shareholders for the three months ended June 30, 2026, were both $(0.69). Basic net income per share attributable to common shareholders for the three months ended June 30, 2025 was $0.51, and diluted net loss per share for the same period was $(1.00), reflecting the dilutive impact of the Company’s convertible notes prior to their conversion into common stock in April 2025.
Cash, cash equivalents
and short-term investments as of June 30, 2026, were $15.8 million, as compared to $30.8 million as of December 31, 2025. Tvardi anticipates that its existing cash, cash equivalents and short-term investments will be sufficient to fund operations, as currently planned, through the HCC topline readout into the third quarter of 2027. Advancing TTI-109 into UC and additional indications will require additional funding and IND clearance.
About Tvardi Therapeutics
Tvardi is a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases with significant unmet need. STAT3 is a central mediator across critical signaling pathways that drive uncontrolled proliferation, survival and immune dysregulation. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. The Company is conducting clinical trials with TTI-109 in healthy volunteers and TTI-101 in hepatocellular carcinoma (NCT05440708). To learn more, please visit tvarditherapeutics.com or follow us on LinkedIn and X (Twitter).
Cautionary Statement Regarding Forward-looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of these forward-looking statements include statements concerning the anticipated benefits of Tvardi’s product candidates; its ongoing clinical trials and anticipated timing of reporting data from such trials; potential indications for its product candidates; its anticipated cash runway; and other statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future, and, therefore, you are cautioned not to place undue reliance on them.
Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are subject to a number of risks, including, among other things: the uncertainties associated with Tvardi’s product candidates, as well as risks associated with the clinical development and regulatory approval of product candidates, including potential delays in the completion of clinical trials or safety or other complications related to its product candidates; the ability to obtain IND clearance for TTI-109 in UC on the timelines expected or at all; the requirement for additional capital to continue to advance these product candidates, which may not be available on favorable terms or at all; the significant net losses Tvardi has incurred since inception; Tvardi’s ability to initiate and complete ongoing and planned preclinical studies and clinical trials and advance its product candidates through clinical development; the timing of the availability of data from Tvardi’s clinical trials; the outcome of preclinical testing and clinical trials of Tvardi’s product candidates, including the ability of those trials to satisfy relevant governmental or regulatory requirements; Tvardi’s plans to research, develop and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of Tvardi’s product candidates; Tvardi’s anticipated cash runway; Tvardi’s ability to attract, hire, and retain skilled executive officers and employees; Tvardi’s ability to protect its intellectual property and proprietary technologies; Tvardi’s reliance on third parties, contract manufacturers, and contract research organizations; the possibility that Tvardi may be adversely affected by other economic, business, or competitive factors; risks associated with changes in applicable laws or regulations; those factors discussed in Tvardi’s filings with the Securities and Exchange Commission, including the “Risk Factors” section of the Annual Report on Form 10-K for the year ended December 31, 2025, and Tvardi’s other documents subsequently filed with or furnished to the SEC, all of which are available on the SEC’s website at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Contacts:
For Tvardi:
Tvardi Investor Relations
[email protected]
PJ Kelleher
LifeSci Advisors
617-430-7579
[email protected]
|
TVARDI THERAPEUTICS Consolidated Balance Sheets (in thousands, unaudited) |
||||||
| June 30, 2026 | December 31, 2025 | |||||
| Assets | ||||||
| Current assets: | ||||||
| Cash and cash equivalents | $15,765 | $20,734 | ||||
| Short-term investments | — | 10,077 | ||||
| Prepaid expenses and other current assets | 1,304 | 727 | ||||
| Total current assets | 17,069 | 31,538 | ||||
| Property and equipment, net | 36 | 52 | ||||
| Intangible assets, net | 291 | 322 | ||||
| Operating lease right-of-use assets | 104 | 144 | ||||
| Other non-current assets | 17 | 17 | ||||
| Total assets |
$ 17,517 |
$ 32,073 |
||||
| Liabilities and Stockholders’ Equity | ||||||
| Current liabilities: | ||||||
| Accounts payable | $4,638 | $3,219 | ||||
| Accrued expenses | 4,352 | 7,707 | ||||
| Operating lease liabilities, current portion | 123 | 116 | ||||
| Total current liabilities | 9,113 | 11,042 | ||||
| Operating lease liabilities, net of current portion | 22 | 85 | ||||
| Total liabilities | 9,135 | 11,127 | ||||
| Stockholders’ equity: | ||||||
| Common stock | 9 | 9 | ||||
| Additional paid-in capital | 132,084 | 131,379 | ||||
| Accumulated other comprehensive income | — | 8 | ||||
| Accumulated deficit | (123,711) | (110,450) | ||||
| Total stockholders’ equity | 8,382 | 20,946 | ||||
| Total liabilities and stockholders’ equity |
$ 17,517 |
$ 32,073 |
||||
|
TVARDI THERAPEUTICS Consolidated Statements of Operations (in thousands, except share and per share data, unaudited) |
||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||
| June 30, 2026 | June 30, 2025 | June 30, 2026 | June 30, 2025 | |||||||||
| Operating expenses: | ||||||||||||
| Research and development | $4,002 | $5,806 | $8,913 | $8,917 | ||||||||
| General and administrative | 2,627 | 3,063 | 4,767 | 4,306 | ||||||||
| Total operating expenses | 6,629 | 8,869 | 13,680 | 13,223 | ||||||||
| Loss from operations | (6,629) | (8,869) | (13,680) | (13,223) | ||||||||
| Interest income | 172 | 377 | 419 | 652 | ||||||||
| Other income, net | — | 12,659 | — | 7,159 | ||||||||
| Net (loss) income |
$ (6,457 ) |
$ 4,167 |
$ (13,261 ) |
$ (5,412 ) |
||||||||
| Net (loss) income per share attributable to common stockholders: | ||||||||||||
| Basic | $(0.69) | $0.51 | $(1.41) | $(1.00) | ||||||||
| Diluted | $(0.69) | $(1.00) | $(1.41) | $(2.04) | ||||||||
| Weighted-average common shares outstanding: | ||||||||||||
| Basic | 9,381,344 | 8,246,582 | 9,381,344 | 5,426,688 | ||||||||
| Diluted | 9,381,344 | 8,455,223 | 9,381,344 | 6,160,967 | ||||||||
